Eligible patients receive individualized treatment recommendations based on their specific goals and clinical profile
Adapting it thoughtfully to GLP-1s preserves access for athletes who need the drugs medically while creating a documentation pathway that addresses the performance-use concerns. Achari said hed also advise paying attention to the gray market for GLP-1s, which he says is enormous and largely invisible. Athletes obtaining research peptides from offshore sources are taking vastly different risks than those who are purchasing FDA-approved medications, including contamination, mislabelling, and inactive compounds
Various effects might be due to different IGF-1 levels
Notable Outcomes Users generally report an improvement in their eating habits
In 2023, a trial of 17,604 adults (SELECT) with obesity and without T2DM, followed for over three years, showed a 20 percent reduction in major adverse cardiovascular events
Thiamin deficiency in people with obesity